Nivolumab, which is already being investigated as a potential treatment for non-small cell lung cancer, melanoma, head and neck cancer, glioblastoma, and both Hodgkin and non-Hodgkin lymphoma, has shown success in early trials involving patients with renal cell carcinoma (RCC). As reported by Bristol-Myers Squibb, results from the phase 2 Checkmate -010 trial demonstrated antitumor activity when used as monotherapy in patients with RCC. A second phase1b study—Checkmate -016—indicate that nivolumab was also successful when used in combination with ipilimumab in patients with RCC. Further data will be presented at ASCO 2014.
Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer. In the Phase 2 CheckMate -010 trial> who received prior anti-angiogenic treatment.